ADVERTISEMENT
Manila Bulletin devider Philippines devider National devider Rollout of 2nd Covid-19 booster shot for immunocompromised individuals to start on April 25—DOH

Rollout of 2nd Covid-19 booster shot for immunocompromised individuals to start on April 25—DOH

Published Apr 22, 2022 01:50 pm

(FILES) In this file photo taken on November 30, 2021 a doctor vaccinates a patient against Covid-19 at a vaccination center in Sonthofen, southern Germany, amid the ongoing coronavirus (Covid-19) pandemic. Germany's parliament on April 7, 2022 rejected a government-backed proposal for mandatory Covid vaccines for people above 60, in a stinging defeat for Chancellor Scholz's coalition. Christof STACHE / AFP

The country will start administering the second Covid-19 vaccine booster shot for immunocompromised individuals on April 25, the Department of Health (DOH) said.

“Sa Lunes, April 25, 2022—magtuturok na po tayo ng second booster dose shots para sa 18-years-old and above na immunocompromised (On Monday, April 25, 2022 — we will begin administering second booster shots for 18-years-old and above who are immunocompromised),” said DOH Undersecretary Maria Rosario Vergeire in a press briefing on Friday, April 22.

“Nationwide po ang ating rollout na nakadepende sa kahandaan ng kani-kanilang mga lokal na pamahalaan (The rollout will be nationwide depending on the readiness of their respective local governments),” she added.

Vergeire said they can receive their second booster shot “as early as three months after their third dose” or first booster shot.

The vaccine brands that will be used for the second booster shot are AstraZeneca, Moderna, Pfizer, Sinopharm, and Sinovac.

Earlier, DOH Secretary Francisco Duque III defined immunocompromised people as those diagnosed with HIV/AIDS, cancer patients, transplant patients, and individuals taking immunosuppressive medicines, among others.

Duque also said that the provision of second booster doses for senior citizens and healthcare workers is still under evaluation by the Health Technology Assessment Council (HTAC).

“So, nauna at mas kumpleto ang mga ebidensya na hawak ng HTAC for the immunocompromised—so, minabuti ng Kagawaran ng Kalusugan na iuna na natin kasi natapos na ang HTAC doon kesa idedelay natin lahat (So, the evidence for the immunocompromised individuals which was evaluated by HTAC was completed— so, the Department of Health decided to roll it out for this sector rather than delaying its implementation),” explained Vergeire.

“Kasunod na rin ang senior citizens at healthcare workers. Kinukumpleto lang po ang assessment, maybe by next week tayo ay makakapaglabas na rin ng rekomendasyon at tayo at pwede na rin natin umpisahan in the next week (The senior citizens and healthcare workers will follow soon. We are just completing the assessment. Maybe next week, we will be able to issue a recommendation and we can start next week),” she added.

Related Tags

second booster shot APRIL 25 immunocompromised individuals Department of Health (DOH)
ADVERTISEMENT
.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1561_widget.title }}

{{ item.title }}
.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1562_widget.title }}

{{ item.title }}
.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1563_widget.title }}

{{ item.title }}

{{ articles_filter_1564_widget.title }}

{{ item.title }}
.mb-article-details { position: relative; } .mb-article-details .article-body-preview, .mb-article-details .article-body-summary{ font-size: 17px; line-height: 30px; font-family: "Libre Caslon Text", serif; color: #000; } .mb-article-details .article-body-preview iframe , .mb-article-details .article-body-summary iframe{ width: 100%; margin: auto; } .read-more-background { background: linear-gradient(180deg, color(display-p3 1.000 1.000 1.000 / 0) 13.75%, color(display-p3 1.000 1.000 1.000 / 0.8) 30.79%, color(display-p3 1.000 1.000 1.000) 72.5%); position: absolute; height: 200px; width: 100%; bottom: 0; display: flex; justify-content: center; align-items: center; padding: 0; } .read-more-background a{ color: #000; } .read-more-btn { padding: 17px 45px; font-family: Inter; font-weight: 700; font-size: 18px; line-height: 16px; text-align: center; vertical-align: middle; border: 1px solid black; background-color: white; } .hidden { display: none; }
function initializeAllSwipers() { // Get all hidden inputs with cms_article_id document.querySelectorAll('[id^="cms_article_id_"]').forEach(function (input) { const cmsArticleId = input.value; const articleSelector = '#article-' + cmsArticleId + ' .body_images'; const swiperElement = document.querySelector(articleSelector); if (swiperElement && !swiperElement.classList.contains('swiper-initialized')) { new Swiper(articleSelector, { loop: true, pagination: false, navigation: { nextEl: '#article-' + cmsArticleId + ' .swiper-button-next', prevEl: '#article-' + cmsArticleId + ' .swiper-button-prev', }, }); } }); } setTimeout(initializeAllSwipers, 3000); const intersectionObserver = new IntersectionObserver( (entries) => { entries.forEach((entry) => { if (entry.isIntersecting) { const newUrl = entry.target.getAttribute("data-url"); if (newUrl) { history.pushState(null, null, newUrl); let article = entry.target; // Extract metadata const author = article.querySelector('.author-section').textContent.replace('By', '').trim(); const section = article.querySelector('.section-info ').textContent.replace(' ', ' '); const title = article.querySelector('.article-title h1').textContent; // Parse URL for Chartbeat path format const parsedUrl = new URL(newUrl, window.location.origin); const cleanUrl = parsedUrl.host + parsedUrl.pathname; // Update Chartbeat configuration if (typeof window._sf_async_config !== 'undefined') { window._sf_async_config.path = cleanUrl; window._sf_async_config.sections = section; window._sf_async_config.authors = author; } // Track virtual page view with Chartbeat if (typeof pSUPERFLY !== 'undefined' && typeof pSUPERFLY.virtualPage === 'function') { try { pSUPERFLY.virtualPage({ path: cleanUrl, title: title, sections: section, authors: author }); } catch (error) { console.error('ping error', error); } } // Optional: Update document title if (title && title !== document.title) { document.title = title; } } } }); }, { threshold: 0.1 } ); function showArticleBody(button) { const article = button.closest("article"); const summary = article.querySelector(".article-body-summary"); const body = article.querySelector(".article-body-preview"); const readMoreSection = article.querySelector(".read-more-background"); // Hide summary and read-more section summary.style.display = "none"; readMoreSection.style.display = "none"; // Show the full article body body.classList.remove("hidden"); } document.addEventListener("DOMContentLoaded", () => { let loadCount = 0; // Track how many times articles are loaded const offset = [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]; // Offset values const currentUrl = window.location.pathname.substring(1); let isLoading = false; // Prevent multiple calls if (!currentUrl) { console.log("Current URL is invalid."); return; } const sentinel = document.getElementById("load-more-sentinel"); if (!sentinel) { console.log("Sentinel element not found."); return; } function isSentinelVisible() { const rect = sentinel.getBoundingClientRect(); return ( rect.top < window.innerHeight && rect.bottom >= 0 ); } function onScroll() { if (isLoading) return; if (isSentinelVisible()) { if (loadCount >= offset.length) { console.log("Maximum load attempts reached."); window.removeEventListener("scroll", onScroll); return; } isLoading = true; const currentOffset = offset[loadCount]; window.loadMoreItems().then(() => { let article = document.querySelector('#widget_1690 > div:nth-last-of-type(2) article'); intersectionObserver.observe(article) loadCount++; }).catch(error => { console.error("Error loading more items:", error); }).finally(() => { isLoading = false; }); } } window.addEventListener("scroll", onScroll); });
Join Our Newsletters

Sign up by email to receive news.

© 2025 Manila Bulletin The Nation's Leading Newspaper. All Rights Reserved.